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The story begins more than 25 years ago, when the initial clinical
observations of a new alarming epidemic were made. In June 1981
clinicians in the United States ﬁrst reported a number of cases of
Pneumocystis carinii in homosexual men (Gottlieb et al., 1981).
Subsequently the ﬁrst cases of what would later be known as AIDS
were observed in France. At the time, I was working at the Institut
Pasteur with Luc Montagnier and Jean-Claude Chermann. In Decem-
ber 1982, we were contacted by clinicians in France who provided us
with a biopsy of lymph node from an AIDS patient, with the aim to
isolate the etiological agent causing the disease.
The hypothesis at the time was that a retrovirus might be the
etiological agent responsible for AIDS. The only human retrovirus
known at that time was the Human T-lymphotropic virus (HTLV),
known to cause transformation of T cells, and arguably it would have
been possible to culture the cells from the lymph node biopsy, and
simply observe for T cell transformation. Luckily we did not assume
that HTLV was necessarily the cause of the disease, and we decided to
sample the culture supernatant every 3 to 4 days to detect for reverse
transcriptase activity. Indeed we started to observe a reverse
transcriptase activity which decreased shortly after, in correlation
with cell death. Initially we were concerned about possible toxicity
related to tissue culture components, but following the addition of
fresh lymphocytes and fresh components to the culture, the same cell
death phenomenon was observed in correlation with the detection of
reverse transcriptase activity. We thus realized that the virus itself
was responsible for this phenomenon.
The isolation of this new human retrovirus (at the time known as
LAV, lymphoadenopathy associated virus) was ﬁrst reported and
published in May 1983 (Barré-Sinoussi et al., 1983). In this ﬁrst report
we described that LAV could be propagated on peripheral blood
mononuclear cells and on cord blood lymphocytes. We also described
the viral protein p25, and importantlywedetermined that therewasno,
or weak, cross reactivity with HTLV-1 proteins, indicating that wewere
dealing with a new human virus. In the same report we demonstrated
the presence of antibodies against LAV in a second patient affected by
AIDS. The report of the virus was, however, just the beginning.☆ This manuscript covers the contents of the Nobel Lecture presented at the
Karolinska Institute, Stockholm, Sweden on December 7, 2008, and it is reprinted with
the permission of The Nobel Foundation.
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doi:10.1016/j.virol.2009.08.033The isolation of the virus was not sufﬁcient however to convince
the scientiﬁc community of the implication of the virus in AIDS. It was
therefore essential to further characterize the virus and establish a
clear link between the virus and the disease to persuade the scientiﬁc
community and the relevant authorities that the newly isolated virus
was the etiological agent responsible for the emerging epidemic. In
1983 we decided to immediately halt all other research projects
which were ongoing in the laboratory (including determining
whether MMTV sequences could be associated with breast cancer —
a hypothesis still valid today) and to mobilize a network of efﬁcient
collaborations with clinicians, immunologists and molecular biolo-
gists. In order to determine whether this newly isolated virus was
truly responsible for the disease affecting AIDS patients, we quickly
developed a serological test to perform sero-epidemiological studies
(Brun-Vezinet et al., 1984). Crucially this same test was subsequently
used as a diagnostic tool for blood testing. The development of the
diagnostic test was made possible by a strong and efﬁcient
partnership with the private sector, namely Sanoﬁ Pasteur.
In 1984 Gallo et al. (1984) and Levy et al. (1984) published reports
conﬁrming the identiﬁcation of the causative agent of AIDS.From bed-side to bench to bed-side
These early years of HIV research were the reﬂection of clinical
observations which prompted basic research in the laboratory, which
in turn resulted in the development of clinical tools. The identiﬁcation
and the initial characterization of the virus led to the ﬁrst diagnostic
tests that permitted blood testing for the virus, and consequently the
prevention of transmission by blood and blood derivatives. The
increasing knowledge of the virus, its proven link to AIDS and its
modes of transmission spurred the ﬁrst programs for voluntary
counseling and testing, and subsequently prevention of sexual
transmission. The knowledge that the virus infected cells bearing
the CD4 receptor (Dalgleish et al., 1984; Klatzmann et al., 1984a,
1984b) and the fact that HIV could be cytopathogenic to CD4
lymphocytes was the basis for CD4 cell monitoring in HIV infected
patients. The characterization of the viral reverse transcriptase
activity provided the rationale for initially using azidothymine
(AZT) as therapy for HIV patients (Broder et al., 1985), and
importantly, as the ﬁrst therapeutic approach to prevent mother-to-
child transmission of HIV. The efﬁciency of AZT alone was rapidly
reported to be limited with regard to the ﬁrst observation of
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ment in the early 1990s of combined therapy, also known as highly
active antiretroviral therapy (HAART). The cloning and sequencing of
HIV (Alizon et al., 1984; Wain-Hobson et al., 1985), performed by
molecular biologists at the Institut Pasteur, provided the necessary
knowledge at the basis of the test to determine the viral load and to
monitor resistance to therapy (Fig. 1).
The cloning and sequencing of HIV also permitted to gain insight
into the tremendous diversity and the origin of HIV. Early studies
indicated that HIV-1 might have resulted from the introduction of a
virus from chimpanzee to humans. A collaboration with the Centre
Pasteur Cameroun identiﬁed a new group of HIV-1, isolated from a
woman with AIDS: the HIV-1 group N, distinct from groups O and M.
Sequencing of simian viruses revealed a chimpanzee virus very closely
related to the HIV-1 N group, in particular in speciﬁc genes (Simon et
al., 1998; Apetrei et al., 2004).
Determinants of HIV pathogenesis
Since the discovery of the virus, we have learnt that HIV infection
is muchmore complex than we initially thought, and the mechanisms
leading to AIDS pathogenesis are still today not entirely understood.
We have, however, gained signiﬁcant insight into the virus and the
evolution of the disease it causes. For example, we now know that
soon after infection by HIV, the virus integrates into the host cells,
establishing permanent reservoirs. Studies have shown that the
evolution of the infection and the progression of the disease is linked
to the viral load: indeed the peak of viral load correlates with a sharp
decrease in the number of CD4 cells, which are partially restored in
relation to the decrease of the viral load. During the last years, we
have made important progress in understanding that HIV infection
causes chronic immune activation. Very early after exposure to the
virus, HIV infected patients are characterized by markers of
generalized and persistent T cell activation. Given the close correla-
tion between immune activation and the disease outcome, markers of
T cell activation may emerge as better prognosis markers for disease
progression than viral load and CD4 cell counts. It is also known today
that HIV infection results in early massive depletion of CCR5+ CD4+ T
memory cells in the gastrointestinal tract, associated with microbial
translocation in the gut. Further studies will be necessary to
determine whether the microbial translocation is a cause or
consequence of the massive T cell depletion (Cadogan and Dalgleish,
2008; Douek et al., 2009).
The evolution and progression of the disease caused by HIV are
closely linked to a number of determinants of both the virus itself and
the host. Indeed each particular path of disease progression isFig. 1. HIV research: from bed-siddetermined by a delicate interplay between viral and host factors.
The virus itself greatly varies: in its tropism and replicative capacity,
as well as the intrinsic immunosuppressive properties of some viral
proteins, all inﬂuencing HIV pathogenesis. A number of host factors
are also important in determining the distinct paths of disease
progression in different HIV infected individuals. The adaptive
immune responses (including CD8 cell and CD4 cell responses) are
ﬁnely tuned in each separate individual, resulting in differential
control of the infection. Equally different genetic polymorphisms of
receptors, ligands, and key immune proteins all result in speciﬁc
modulations of the host response to HIV infection. Recently it has
become apparent that humans and non-human primates possess a
number of proteins capable of restricting HIV/SIV infection, and
therefore play crucial roles in intracellular innate immunity. In brief,
therefore, the speciﬁc evolution of the disease caused by HIV is the
result of an intricate interplay between the virus and the host.
Natural models of HIV/AIDS protection
Natural models provide key insight into the mechanisms that
underlie protection against HIV infection and disease progression.
A very small number of individuals (known as exposed uninfected,
EU) appear to be resistant to infection, despite repeated exposure to
HIV. A study performed in collaboration in Vietnam analyzed two
groups of intravenous drug users (IDU) who routinely exchanged
needles for drug injection. Despite both groups being infected with
hepatitis viruses and HTLV, one group was consistently negative for
HIV in both serological and PCR tests. To address the mechanisms
involved in this natural protection against infection by HIV, the innate
immune responses of the two groups were compared. The two groups
were characterized by a signiﬁcant difference in the activity of the
natural killer (NK) cells; in fact the EU group of Vietnamese IDU
typically showed an increased level of NK cell activity (Ravet et al.,
2007). We further analyzed the NK cell repertoire associated with this
increased activity. The analysis revealed an increased ratio of speciﬁc
NK receptors in EU compared to control or HIV infected individuals.
Furthermore, the functional activated NK cells in EU express
signiﬁcantly higher levels of the CD161 receptor than control
individuals, suggesting that a speciﬁc subset of NK cells in EU might
be involved in their protection against HIV infection.
Another insightful model which permits us to shed light on some
of the mechanisms providing protection against HIV is provided by
the few individuals who, despite being infected by the virus, are
capable of controlling its replication. These rare individuals (known as
HIV controllers, or elite controllers) are deﬁned by having been
infected for more than 10 years while presenting undetectable plasmae to bench, back to bed-side.
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reported that the CD8 T lymphocytes of HIV controllers possess HIV
suppressive capacities, being able to suppress HIV replication in the
CD4 T cells (Saez-Cirion et al., 2007a, 2007b). The majority of HIV
controllers included in this ﬁrst study possess CD8 T cells capable of
eliminating infected CD4 T cells. Further analyses showed that the
CD8 T cells of HIV controllers were activated, but to a lesser extent
than in HIV progressors. Although the majority of HIV controllers
appear to possess suppressive CD8 T cells, some individuals are not
characterized by this trait while still controlling efﬁciently the virus.
This observation indicates that there is likely more than one immune
mechanism contributing to the tight control of HIV replication in
these lucky few individuals.
Animal models represent a key component of many domains of
biomedical research. HIV and its closely related counterpart, the
simian immunodeﬁciency virus (SIV) are strictly primate-speciﬁc
viruses so simian models which are susceptible to SIV infection, play a
key role in understanding infection and disease progression. Most
naturally infected African primates, like the African Green Monkey
(AGM) do not develop AIDS, in contrary to the Asian rhesus macaque;
they therefore provide a unique model to investigate protective
mechanisms against AIDS (Silvestri, 2008; Liovat et al., 2009).
Interestingly, SIV is capable of replicating in both pathogenic and
non-pathogenic simian models suggesting that viral replication is not
the only key determinant of an AIDS outcome. Both models show a
massive depletion of CCR5+ CD4+ cells in the gastrointestinal tract.
Partial restoration of CD4+ cells and the absence of apoptosis,
however, ensure that the intestinal mucosa remains intact in the
non-pathogenic model, therefore impeding microbial translocation.
Comparative analyses between the two primate models show that T
cell activation during the chronic phase of viral infection is a key
difference between the non-pathogenic and the pathogenic infec-
tions. Indeed chronic T cell activation is the hallmark of HIV-1
infection in humans and pathogenic SIV infection in rhesus macaques.
The proﬁles of T cell activation are determined by the innate immune
responses, mediated in particular by dendritic cells. The rhesus
macaquemodel shows a more persistent recruitment of plasmacytoid
dendritric cells (PDC, the principal producers of interferon-α) to the
lymph nodes (Diop et al., 2008; Kornfeld et al., 2005). More recently
we have used microarrays to compare the gene proﬁles of the two
primate models. This technique has allowed us to observe that
interferon type 1 pathways are activated in both models, but only
transiently in the non-pathogenic model in the very early phases of
infection. This observation contributes to the hypothesis that key
events that determine the disease progression occur in the very early
stages of infection. Important differences are observed in the early
acute phase of SIV infection in the non-pathogenic and pathogenic
models, including a higher induction of pro-inﬂammatory cytokines
in the pathogenic model (Fig. 2).
The early acute phase of HIV infection appears therefore to be
crucial in determining disease progression. Given the importance ofFig. 2. Non-pathogenic versus pathogenic SIV infection — early acute phase markers.this very early phase following infection, the role of the innate
immune system, our body's ﬁrst line of defense against infections,
should strongly be considered.
More detailed insight into the role of the innate immune system in
HIV has been gained by an in vitro model of a co-culture of natural
killer (NK) cells and dendritic cells (DC), which are natural target cells
of HIV infection. This in vitromodel has highlighted that the expression
of a number of NK cell surface receptors, in particular the CD85j
receptor, is reducedwhen the cells are in contactwith infected DCs.We
also observed that the subpopulation of NK cells which express the
CD85j receptor is capable of strongly suppressing HIV replication in
DCs (Scott-Algara et al., 2008). This suppression is only partially
relieved by incubation with monoclonal antibodies against HLA class I
(the natural ligands of CD85j) but strongly abolished by incubation
with a recombinant CD85j protein, suggesting that the interaction
between the CD85j and a peculiar (as of yet unknown) ligand might
result in signaling pathways necessary for suppression.
Future research will need to focus on understanding in greater
detail the complex cross-talk between DC, NK and T cells during HIV
infection, as well as the modulation of signaling pathways and soluble
factors which can inﬂuence disease progression (Fig. 3).
HIV/AIDS: The state of the epidemic in 2008 and future directions
At the end of 2007 33 million people lived with HIV, 2.7 million
were newly infected and a further 2 million died of AIDS (UNAIDS,
2008). These numbers demonstrate that HIV/AIDS still remains a
crucial global health issue. Since the discovery of HIV, enormous
progress has been made in the development of antiretroviral (ARV)
drugs, and in expanding their availability to those who require
treatment. In 2002 approximately only 2% of people needing
treatment received it; this ﬁgure has since increased to 30% in 2008.
Despite this massive increase in access, for every new person starting
ARV treatment, 2–3 new cases of HIV infection are reported. The
beneﬁts of ARV are irrefutable; their importance is clearly illustrated
in Botswana where the introduction of ARV in 2002 has been followed
by a decrease in the number of AIDS-related deaths in the country.
Despite the immense beneﬁts of ARV treatment, many issues still
need to be tackled. ARV treatment remains a life-long commitment
with consequent economical limits. Moreover, life-long treatment is
associatedwith the emergence of drug resistance, metabolic disorders
and cancers. In the absence of a cure for HIV, it is essential to continue
investigating and promoting all prevention measures. The accom-
plishment of prevention programs for HIV infection have been proven
by the success in limiting sexual transmission (mainly through the
promotion of condom use) and in limiting mother-to-child transmis-
sion of HIV by improving diagnosis and introducing ARV treatment to
pregnant HIV+ women. Research on prevention methods continues,
and recently we have also learnt that male circumcision can diminish
the risk of infection, and therefore could be considered as part of a
comprehensive prevention plan. Prevention programs which are
currently being investigated include pre- and post-exposure prophy-
laxis, and further research directed on speciﬁc anti-viral microbicides,
which so far have only provided disappointing results, could lead to
beneﬁcial outcomes.
Despite innumerable advances in the ﬁeld of HIV research over the
last 25 years, many new aspects of HIV infection and immunopatho-
genesis are still emerging. It is clear that there are currently many
areas in HIV research which require investigation, and many domains
will beneﬁt from a strong emphasis on basic research. Further insight
into the very early stages of HIV infection, including the establishment
of viral reservoirs and the immune responses induced is crucial for the
development of novel therapeutic and vaccinal strategies. Future
directions for new intervention strategies, which should be investi-
gated in further detail, include, for example, the identiﬁcation of new
targets and the use of siRNA to restrict HIV infection. The recent years
Fig. 3. Potential mechanisms of HIV control. The control of HIV may be determined by a complex interplay between innate and adaptive immune systems. Natural killer (NK) cells
might control HIV by directly eliminating infected cells or by providing the optimal cytokine environment. HIV-speciﬁc CD8 cells with cytotoxic properties could also play a key
role in controlling HIV infection. Other control mechanisms include the production of neutralizing antibodies and intracellular restriction factors which counteract the HIV
replicative cycle.
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disease progression; if microbial translocation is conﬁrmed to be
responsible, at least in part, for this immune activation, drugs limiting
microbial translocation need to be considered as alternative thera-
peutic strategies.
Co-infection between HIV and other diseases should not be
overlooked. Co-infections in HIV+ patients are currently an acute
public health issue, and further clinical attention and basic research is
required to address this delicate problem. A salient example is
provided by the co-infection of HIV and tuberculosis: in sub-Saharan
Africa and other resource-limited regions, tuberculosis is a major
cause of death among HIV positive people.
An effective vaccine against HIV represents the ultimate preven-
tion approach. HIV, however, exhibits several scientiﬁc challenges.
HIV is a virus characterized by a high degree of genetic variability,
aiding the virus to evade the human immune system. Furthermore the
very early establishment of viral reservoirs, characteristic of HIV,
hinders the development of an effective vaccine. To add to the
complexity, HIV is transmitted not only by cell-free virus, but also by
cell-to-cell contact, and it is still unclear as to which mechanisms are
necessary to impede cell-to-cell transmission. To progress in the
development of an effective vaccine it is essential to understand the
complex dysfunctions of the immune system which are more rapidly
induced than the speciﬁc immune response by HIV following
infection. A key step in the development of an effective vaccine will
be the identiﬁcation and deﬁnition of the viral determinants
responsible for early pathogenic signals and mechanisms to preventFig. 4. HIV vaccine research: re-thinking future strategies.such harmful pathogenic pathways (Barouch, 2008; Haynes and
Shattock, 2008; Walker and Burton, 2008) (Fig. 4). In addition to the
indispensable advances in basic science, the development of an
effective HIV requires innovative and creative HIV vaccine strategies,
within the context of a clearly deﬁned international agenda to
promote collaboration.
Beneﬁts beyond HIV/AIDS
HIV can be a powerful tool for unraveling future scientiﬁc
knowledge. Research on HIV has signiﬁcantly contributed to the
understanding of the delicate relationship of virus and host interactions.
Continued effort to understand this complex virus has also revealed
new cellular partners which may be involved in controlling infection.
HIV can also help identify new receptors and ligands and new signaling
pathways. Future research on understanding the immune responses
induced by HIV will provide more information on the complex cross-
talk between innate and adaptive immunity. This cross-talk between
innate and adaptive immunity is crucial for the induction of effective
immune responses to infections, and the elucidation of these mechan-
isms will prove important for other diseases as well.
Given the complexity of developing an effectiveHIV vaccine,weneed
to think of new innovative and creative concepts and strategies for
vaccines. These new strategies may likely prove useful for the
developmentof vaccines against other infectious diseases or even cancer.
The use of lentiviral vectors in gene therapy for a number of
diseases, including cystic ﬁbrosis andmuscular dystrophy, has already
been widely investigated. Despite some setbacks, new promisingFig. 5. Beneﬁts beyond HIV: global health systems improvement.
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research may provide new therapeutic strategies.
Improving global health: A key role of the ﬁght against HIV/AIDS
Importantly, the ﬁght against HIV is also a key element in the
improvement of global health. It is now widely recognized that
investment in health is one of the key components of sustainable
development. International efforts in close collaborationwith national
programs in HIV/AIDS have promoted an overall amelioration of
global health, which is not limited to people living with HIV. Global
interventions in HIV/AIDS reinforce local infrastructure, contribute to
capacity building and increase human resources contributing greatly
to better overall health in the country (Fig. 5).
The effect of HIV/AIDS interventions in general public health
improvement is exempliﬁed by the case of Cambodia. In 1994–95,
following the decline of the Khmer Rouge regime, we started working
in collaboration with Cambodia. At the time, human resources were
extremely limited, if at all existent. We and others quickly started to
train people, who were very keen and determined to learn about
progress in science and medicine. In 1995, the ﬁrst Voluntary and
Conﬁdential Counselling and Testing (VCCT) site was created at the
Pasteur Institute in Cambodia. Over the years, we and others have
been working to improve the quality of human resources in the
country, and the quality of health infrastructures and the number of
VCCT sites has greatly increased to more than 200 in the entire
country in 2008. A similar trend was noted in clinical sites for
treatment of opportunistic infections and antiretroviral therapy.
These sites are present in the entire country, covering a large part of
the territory, and the services provided are not only HIV monitoring
and treatment but also care for other infections. Today, approximately
30,000 patients are under antiretroviral therapy and Cambodia may
well be one of the ﬁrst countries to reach the objective of universal
access by the year 2010. Such progress would not have been possible
without the strong political determination of the local government.
Although the road ahead is still long, we are on the right path to
achieve a world without AIDS. This goal will be reached by following a
model of research, echoing the tradition of Louis Pasteur: continued
basic and clinical research, investment of both public and private
sectors, public health interventions and the participation, which should
be strongly acknowledged, of people living with HIV/AIDS themselves.
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